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Bronchoalveolar Lavage-microRNAs Are 
Potential Novel Biomarkers of Outcome  
After Lung Transplantation
Alessandro Palleschi, MD,1 Gabriella Gaudioso, PhD,2 Valeria Edefonti, PhD,3 Valeria Musso, MD,1,4  
Andrea Terrasi, BSc,2 Federico Ambrogi, PhD,3 Sara Franzi, PhD,1 Lorenzo Rosso, MD,1,5 Paolo Tarsia, MD,6  
Letizia C. Morlacchi, MD,4,6 Stefano Ferrero, MD,2,7 Mario Nosotti, MD,1,4 and Valentina Vaira, PhD2
Lung transplantation (LTx) is the gold standard treatment for chronic end-stage pulmonary diseases. Survival of 
LTx patients has improved recently due to advances in surgical 
techniques and pharmacologic management of complications. 
However, the mortality rate in the first year after transplant 
remains high, mostly due to acute lung allograft dysfunction 
(ALAD) events, such as acute cellular rejection or infections.1 
The pathogenetic mechanisms underlying this phenomenon 
remain puzzled, and the correct clinical approach has yet to be 
firmly established. The influence of ALAD in this early period 
on mid- and late-term outcomes is a topic of intense interest.
Lung Transplantation
Background. Primary graft dysfunction, infections, and acute rejection (AR) worsen lung transplantation (LTx) outcome 
and patient survival. Despite significant efforts, reliable biomarkers of acute lung allograft dysfunction are lacking. To address 
this issue, we profiled the bronchoalveolar lavage (BAL) miRNome in LTx patients. Methods. BAL-microRNAs (miRNAs) 
from 16 patients were collected 7 days (T0), 15 days (T1), and 3 months (T2) after bilateral LTx and profiled on low-density 
array. Unsupervised and supervised analyses were used to identify miRNAs associated with clinical features, pneumonia, or 
AR. Prognostic markers were identified using the Cox model. Targeted signaling pathways were predicted in silico. A second 
series of 11 patients were used to validate AR-associated miRNAs. Results. Variation in BAL-miRNAs was associated 
with acute lung allograft dysfunction. Increased levels of miR-23b-3p at T2 were detected in patients with pneumonia, 
whereas let-7f-5p, miR-146b-3p, miR-22-5p, miR-29c-5p, miR-362-5p, and miR-452-5p were upregulated at T2 in patients 
with AR. miR-148b-5p and miR-744-3p distinguished LTx patients with AR in both cohorts. Low miR-148b-5p and high 
miR-744-3p expression levels were significantly associated with a shorter time to AR either within the first year after LTx or 
during follow-up. Combination of the 2 miRNAs identified LTx patients with higher AR risk independently of clinical variables. 
Conclusions. Our data provide new insights into the roles of BAL-miRNAs in regulating the pulmonary environment after 
transplantation and suggest that these miRNAs could serve as biomarkers of early- or mid-stage events. If validated, these 
findings could pave the way to a personalized clinical approach in LTx patients.
(Transplantation Direct 2020;6: e547; doi: 10.1097/TXD.0000000000000994. Published online 9 April, 2020.)
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MicroRNAs (miRNAs) are small noncoding RNAs that 
regulate gene expression, usually by silencing their target 
mRNAs. These molecules are powerful regulators of various 
diseases, with potential critical effects on disease initiation, 
progression, and treatment. A single miRNA can alter the 
expression of many target genes, thereby influencing entire 
signaling pathways rather than a single gene. This unique 
function makes miRNAs attractive targets for translational 
medicine. miRNAs are ideal circulating diagnostic, prog-
nostic, and predictive biomarkers of disease status and are 
also present in bronchoalveolar lavage (BAL).2,3 Various 
studies have provided evidence that miRNAs play a funda-
mental role in respiratory disorders and several other physi-
ologic and pathologic mechanisms, including immune cell 
development and function, inflammation, and oncogenesis. 
Preliminary work has shown that miRNAs are dysregulated 
following LTx.4
Hence, we sought to preliminary characterize differences in 
BAL-miRNA profiles, or their variation over time, according 
to features related to the recipient, donor, surgical procedure, 
or posttransplantation complications and to identify predic-
tive markers of the onset of acute rejection (AR) in the first 
year after transplantation.
MATERIALS AND METHODS
Patients
We conducted a single-institution prospective study 
at Fondazione IRCCS Ca’ Granda—Ospedale Maggiore 
Policlinico of Milan. The local Ethical Committee approved 
the study (protocol No. 640/2017bis) and informed written 
consent was obtained from all subjects. For the study, we 
enrolled all patients who underwent bilateral LTx at our insti-
tution between May 2017 and July 2018. A first set of 16 
patients was used for miRNA screening, whereas additional 
11 patients were included in data validation analyses.
Exclusion criteria were as follows: patients who declined to 
participate, age < 18 years, previous solid organ transplanta-
tion, intensive care unit (ICU) stay > 15 days, and death within 
1 week after surgery. Patients underwent bronchoscopic sur-
veillance with BAL fluid withdrawal at 7 (T0) and 15 days 
(T1) after surgery. Pulmonary trans-bronchial biopsies with 
BAL sampling were scheduled at 3 (T2), 6, and 12 months 
after transplantation, as well as in cases of lung function 
decline or another clinical suspicion of ALAD. Our proto-
cols for donor and recipient selection, graft procurement, 
and transplantation surgical procedures are described in the 
online supplement http://links.lww.com/TXD/A248.
For each LTx recipient, the following clinical data were 
collected: data regarding the primary lung disease, age, sex, 
lung allocation score, microbial colonization (in patients with 
cystic fibrosis [CF]), and cytomegalovirus serology. Donor 
data obtained during organ procurement included donor age 
and sex, smoking history, type of donation (donation after 
brain death or donation after circulatory death, respectively), 
Oto score, cytomegalovirus serology, donor/recipient mis-
match, and use of static or portable machine perfusion (MP). 
We also recorded data on intraoperative extracorporeal mem-
brane oxygenation, mechanical ventilation (MV), and warm 
ischemic time. For postoperative variables, we recorded pri-
mary graft dysfunction (PGD) score, best forced expiratory 
volume in the first second (FEV1), pneumonia, histological 
(grade A and B), and clinical AR (c-AR) in the first year after 
transplantation. c-AR occurrence during the complete follow-
up time (ended in July 2019) was also recorded. Definition of 
clinical variables is provided in the Supplementary Methods.
Sample Collection
T0, T1, and T2 BALs were centrifuged at 2500  revolutions 
per minute at 4°C for 15 minutes to remove cell debris; the 
supernatant was aliquoted into RNase-free tubes and stocked 
at –80°C until RNA purification. miRNA profiling proce-
dures were described previously5,6 and are also provided in 
the online supplement http://links.lww.com/TXD/A248.
Data Collection and Statistical Analysis
miRNA data were analyzed using both unsupervised and 
supervised approaches. Calculations were carried out in the R 
statistical computing environment using the libraries Biobase, 
perm, nparLD, Hmisc, survival, factoextra, FactoMineR, 
NbClust, and ComplexHeatmap.1,7 For unsupervised analysis, 
normalized miRNA quantities were imported in Rstudio, and 
the ComplexHeatmap package in Bioconductor was used for 
hierarchical clustering analysis. Principal component analysis 
plots were generated in R (https://cran.r-project.org/) to visu-
alize LTx patients’ distribution according to the miRNome at 
individual times, as described.8 The K-means clustering algo-
rithm was used to visualize sets of co-regulated miRNAs at 
individual time points.
Differences in miRNA expression according to clinical 
features (all treated as categorical variables) were performed 
either separately at individual time points (T0, T1, and T2) 
or as variations of each miRNA during follow-up (ie, the fol-
lowing 3 combinations: T1–T0, T2–T0, and T2–T1). For the 
first analysis, differentially expressed miRNAs according to 
clinical or outcome variables were identified by computing 
the fold change (log2Ratio) between the 2 classes and apply-
ing the Kolmogorov-Smirnov test. Time-dependent variations 
of miRNA levels during T0, T1, and T2 were examined in 
relation to clinical features using nonparametric repeated-
measures ANOVA. Specifically, a model with an interaction 
of time and clinical feature, such as pneumonia or c-AR, was 
considered for each miRNA. Pneumonia or c-AR were treated 
as a binary variables. We evaluated if levels of miRNAs at 
T0, T1, and T2 schedules varied differently in patients with 
c-AR compared with patients who did not experienced acute 
graft rejection. The accuracy of the data was assessed by a 
permutation-based estimate of the false discovery rate (FDR). 
Accordingly, all P values were corrected for multiple compari-
sons using the FDR approach, with the FDR threshold set to 
10%. The associations between pairs of variables were inves-
tigated using Fisher exact test (MedCalc software).
The impact of clinical or molecular variables on the inci-
dence of c-AR was analyzed by univariate or multivari-
ate analysis using the Cox proportional-hazards regression 
model. The miRNA level cutoffs used to sort LTx patients into 
low and high expression groups were generated using receiver 
operating characteristic (ROC) curves and Youden’s J statistic, 
as described.8 Kaplan-Meier survival curves were compared 
using log-rank and Gehan-Breslow-Wilcoxon tests. Logistic 
regression model was used to calculate odds ratio associated 
to c-AR (dependent variable). When a multivariate model was 
performed, the stepwise method was used. All of these analy-
ses were performed using MedCalc software.
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.  3Palleschi et al
Lists of target genes were created using the miRTargetLink 
Human tool (https://ccb-web.cs.uni-saarland.de/mirtar-
getlink/), which provides a list of experimentally validated 
miRNA targets or with the multiMiR R package and database 
in Bioconductor when validated targets were unavailable. Gene 
lists were then either analyzed using the Over Representation 
Analysis within the WEB-based GEne SeT AnaLysis Toolkit 
using the human protein-coding genome as reference set (www.
webgestalt.com) and enrichment of significant Gene Ontology 
category Biological Process was performed.
Data are presented as mean ± SEM or median ± interquartile 
range, as specified in the legend.
RESULTS
Clinical Data
From May 2017 to July 2018, 37 patients underwent bilat-
eral LTx at our institution. One patient was excluded for pre-
vious liver transplantation, 2 patients were either < 18 or > 65 
years old at the time of transplantation, 1 patient received 
a single LTx, 1 patient did not consent to participate in the 
study, and 2 patients had a prolonged ICU stay. Moreover, 
for 3 patients, the BAL at T0 was not suitable for RNA puri-
fication because of hemolysis. Therefore, 27 patients were 
ultimately enrolled in the study, of whom 16 were included 
in the discovery analysis and 11 were available to data con-
firmation (Table 1 and Table S1, SDC, http://links.lww.com/
TXD/A248). Patients’ median age was 34 years (range, 21–64 
y), and 19 were men. Nineteen subjects suffered from CF, 
whereas 8 had interstitial lung disease. Mean follow-up time 
was 18 months (range, 12–25 mo), during which 4 patients 
died. Patient characteristics are presented in Table  1 and 
Table S1 (SDC, http://links.lww.com/TXD/A248). For 1 and 
4 patients, respectively, T1-BAL or T2-BAL was not suitable 
for molecular analysis due to hemolysis. A Consort flow chart 
is provided in the online supplement (Figure S1, SDC, http://
links.lww.com/TXD/A248).
miRNA Expression in BAL Undergoes a Global 
Change 3 Months After Transplantation
Initially, we examined the BAL-miRNome in an unsuper-
vised manner to determine whether any phenotypes were 
shared between classes of patients or timing of BAL with-
drawal. To this end, the first series of patients was used 
(n = 16; discovery set). In total, 317 miRNAs were available 
for analysis. We observed a global change in miRNA levels 3 
months after transplantation (T2-BAL) relative to T0 and T1 
(Figure 1A). To determine which signals were most affected 
at earlier (T0 and T1) versus later times (T2), we performed 
k-means clustering analysis of miRNAs, which identified 3 
main groups of miRNAs (Figure 1A). BAL-miRNAs belong-
ing to clusters 1 and 2 were more likely to be represented at 
earlier times, whereas miRNAs belonging to cluster 3 were 
more likely to be expressed at T2. When we analyzed poten-
tially targeted signaling pathways, we found that regulation 
of responses to stress, immunity, wounding, and vasculature 
development were predicted as targets of T0- and T1-miRNAs 
(Figure 1B; Table S2, SDC, http://links.lww.com/TXD/A248), 
whereas genes related to cell death and gene silencing were 
identified as potential targets of T2-miRNAs (Figure  1C; 
Table S3, SDC, http://links.lww.com/TXD/A248). These data, 
although preliminary, shed light on the dynamic biology in the 
lung microenvironment after LTx.
The BAL-miRNome Can Distinguish Patients With 
Distinct Clinical Phenotypes
Next, we analyzed the BAL-miRNome at individual time 
points by unsupervised principal component analysis to 
determine whether miRNAs could discriminate among LTx 
patients according to their clinical features. miRNA pro-
files obtained at T0 discriminated according to disease, Oto 
score, and PGD (Figure 1D; variance explained by the first 
3 components = 59%), whereas T1-miRNAs discriminated 
according to PGD (Figure  1E; variance explained by the 
first 3 components = 63%), and T2-miRNAs discriminated 
according to c-AR (Figure 1F; variance explained by the first 
3 components = 66%).
Variation in BAL-miRNAs Over 3 Months, Rather 
Than Evaluation of miRNAs at Individual Time 
Points, Provides Preclinical Biomarkers of Lung 
Allograft Outcome
Next, we sought to identify BAL-miRNA signatures associ-
ated with recipient-, donor-, and surgery-related clinical fea-
tures (Tables S4–S6, SDC, http://links.lww.com/TXD/A248) 
or posttransplantation variables including PGD grade 2 and 
3, the best FEV1, c-AR, or infections (Table S7, SDC, http://
links.lww.com/TXD/A248). For this purpose, we consid-
ered either BAL-miRNAs obtained at individual time points 
(Tables S3–S7, SDC, http://links.lww.com/TXD/A248) or 
variation in miRNA levels across the 3 periods (nonparamet-
ric repeated-measures ANOVA; Table S8, SDC, http://links.
lww.com/TXD/A248). According to the FDR criterion, 55 
T0-miRNAs were associated with MP (Table S6, SDC, http://
links.lww.com/TXD/A248), and 10 T2-miRNAs were associ-
ated with prolonged warm ischemia, but no miRNAs were 
significantly associated with either pneumonia or c-AR (Table 
S7, SDC, http://links.lww.com/TXD/A248). Conversely, 
repeated-measures ANOVA showed significant time-depend-
ent interactions of miRNAs levels according to pneumonia 
or c-AR. Indeed the variation in miRNA levels across differ-
ent time points provided signatures of 1 and 9 BAL-miRNAs 
associated with pneumonia and c-AR (treated as binary varia-
bles), respectively (Table S8, SDC, http://links.lww.com/TXD/
A248). In general, the increase in expression of the identified 
BAL-miRNAs at T2 versus T1 was associated with a clinical 
event. Specifically, miR-23b-3p expression was elevated at T2 
in patients with pneumonia (Figure  2A), whereas let-7f-5p, 
miR-146b-3p, miR-22-5p, miR-29c-5p, miR-362-3p, and 
miR-452-5p levels were higher at T2 than at T1 in patients 
with AR (Figure 2B). Interestingly, miR-29c-5p levels in BAL-
T1 were increased in cases with PGD grade 2 and 3 (Table 
S7, SDC, http://links.lww.com/TXD/A248) and in BAL-T2 of 
patients with c-AR (Figure 2B).
Based on our in silico analysis of potential predicted targets 
(Table S9, SDC, http://links.lww.com/TXD/A248), mRNAs 
involved in cell dedifferentiation and metabolism were tar-
geted by c-AR-associated BAL-miRNAs (Figure  2C; Table 
S10, SDC, http://links.lww.com/TXD/A248).
Clinical Variables Are Not Able to Discriminate 
Patients With Clinical AR
Next, we explored the possible associations between pairs 
of features related to recipient, donor, or surgical procedure, 
or their associations with patient outcome. Based on Fisher 
exact test, we found that a lung allocation score above 40 was 
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FIGURE 1. Exploratory analysis of the bronchoalveolar lavage (BAL)-miRNome in lung transplantation (LTx) patients. A, Unsupervised 
hierarchical clustering of all BAL-microRNAs (miRNAs) (n = 317) detected in lung-transplanted patients (study phase I, n = 16). BAL samples 
were collected 7 d (T0), 15 d (T1), or 3 mo (T2) after transplantation. The heatmap shows miRNA levels in all patients at the indicated times. 
Red and blue indicate high and low expression, respectively. To identify groups of miRNAs with similar behavior, k-means clustering analysis 
was performed, yielding 3 miRNA clusters (color bar to the right of the heatmap). B and C, Biological processes potentially affected by the 
top miRNAs in k-means clusters 1 and 2 (B) or cluster 3 (C) target prediction was performed for top miRNAs using the miRTargetLink Human 
tool, and gene lists were annotated using WebGestalt and GeneOntology as functional database. Significant terms networks are presented as 
directed acyclic graph (DAG). D–F, Principal component analysis was performed for BAL-miRNAs at T0 (D), T1 (E), and T2 (F) to evaluate the 
sample distribution according to the indicated clinical variable. The variance explained by the first 3 components was as follows: T0 (PC1: 29%, 
PC2: 19%, PC3: 11%); T1 (PC1: 33%, PC2: 17%, PC3: 13%); and T2 (PC1: 47%, PC2: 10%, PC3: 9%). c-AR, clinical acute rejection; CF, 
cystic fibrosis; CMV, cytomegalovirus; ECMO, extracorporeal membrane oxygenation; h-AR, histological acute rejection, grade A; IPF, idiopathic 
pulmonary fibrosis; N, no; PC, principal component; PGD, primary graft dysfunction, Y, yes.
6 Transplantation DIRECT   ■   2020 www.transplantationdirect.com
FIGURE 2. Changes in bronchoalveolar lavage (BAL)-microRNA (miRNA) levels are associated with pneumonia or clinical acute rejection 
(c-AR). The time-dependent interaction of BAL-miRNAs with presence of pneumonia (A) or c-AR (B) was analyzed by nonparametric repeated-
measures ANOVA with correction for multiple comparisons (see also Table S8, SDC, http://links.lww.com/TXD/A248). This analysis was 
performed using the first series of patients (n = 16; see also Figure S1, SDC, http://links.lww.com/TXD/A248). miRNAs whose levels were 
significantly elevated at T2 are shown. C, Vulcano plot showing the biological processes potentially affected by c-AR-miRNAs. Target prediction 
was performed using the miRTargetLink Human tool, and gene lists were annotated using WebGestalt and GeneOntology as functional 
database. FDR, false discovery rate; RQ, relative quantity.
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significantly associated with extracorporeal membrane oxy-
genation, whereas MP procedure was associated with dona-
tion after circulatory death and with an Oto score > 5 (Table 
S11, SDC, http://links.lww.com/TXD/A248). In regard to 
patient outcome, an Oto score > 5 or prolonged MV was asso-
ciated with PGD. Prolonged warm ischemia was associated 
with pneumonia and pneumonia with AR (P = 0.04; Figure 
S2A, SDC, http://links.lww.com/TXD/A248). Finally, we had 
concordance between c-AR and histological AR (grade A) 
evaluated on trans-bronchial biopsies during patients’ surveil-
lance (Figure S2B, SDC, http://links.lww.com/TXD/A248).
miR-148b-5p and miR-774-3p Are Novel Potential 
Predictive Biomarkers of Clinical AR
Lastly, we sought to determine whether clinical or molecu-
lar variables could predict the occurrence of c-AR during the 
follow-up period using the Cox model. In univariate analyses, 
no clinical features were significantly associated with patient 
outcome (Table 2). Using the first set of patients, we found that 
4 T0-BAL miRNAs, miR-27a-5p, miR-148b-5p, miR-222-5p 
and miR-744-3p, and the T1-BAL miRNA miR-1285-3p (Table 
S12, SDC, http://links.lww.com/TXD/A248), were associated 
with c-AR risk within the first year after LTx. However, these 
molecular markers did not meet the criterion for significance 
following the FDR correction for multiple testing (Table S12, 
SDC, http://links.lww.com/TXD/A248). ROC analysis showed 
that T0-BAL miR-148b-5p and miR-744-3p could classify LTx 
patients according to c-AR with an area under the curve > 75% 
(Figure 3A and B), whereas miR-27a-5p, miR-222-5p, and miR-
1285-3p did not (Figure S3, SDC, http://links.lww.com/TXD/
A248). To support this preliminary observation, we extended 
miR-148b-5p and miR-744-3p evaluation including additional 
11 LTx patients (total cohort n = 26 because the patient LTx_16 
was excluded from c-AR analysis due to concurrent pneumonia 
infection; see also Table 1) for whom at least 1-year of follow-up 
was available (range, 12–17 mo; Table 1). Firstly, the ROC iden-
tified cutoffs for the 2 miRNAs (Youden’s J statistic; Figure 3A 
and B) significantly categorized patients according to AR occur-
rence (Figure 3C and D). Moreover, the ROC-generated cutoffs 
for both miRNAs could sort patients into 2 groups with sig-
nificantly different risks of c-AR occurrence either in the first 
year from LTx (Figure 3E and F) or during the entire follow-
up (range 12–25 mo; Figure 3G and H). Specifically, patients 
with higher levels of miR-148-5p in T0-BAL (miR-148b-5pHIGH; 
Figure 3E–G) had a lower risk of c-AR (P = 0.009 or P = 0.004, 
hazard ratio = 0.1 or 0.13 by log-rank test) than miR-148b-
5pLOW subjects. By contrast, lung-transplanted patients with 
high miR-744-3p levels measured in BAL at T0 were charac-
terized by a higher risk of c-AR (P = 0.03 and P = 0.04, hazard 
ratio = 5.6 or 3.8; Figure 3F–H).
The ability of these 2 miRNAs to identify patients at higher 
risk of AR was further strengthened when we combined them, 
categorizing patients as miR-148b-5pHIGH and miR-744-3pLOW 
(both associated with better outcome; n = 10), miR-148b-5pLOW 
and miR-744-3pHIGH (both associated with poorer outcome; 
n = 7), or discordant (either miR-148b-5pLOW and miR-744-3pLOW 
or miR-148b-5pHIGH and miR-744-3pHIGH; n = 9). LTx patients 
with combinations of “good,” “discordant,” or “bad” miRNA 
classes had respectively smaller (18%), intermediate (28%), 
and larger (85%) incidence of c-AR (P = 0.01 by chi-square test; 
Figure 4A). Furthermore, using a logistic regression model we 
determined that the “bad” miRNA class had the strongest pre-
dictive value for c-AR within the first year after LTx (odds ratio, 
25; 95% confidence interval, 1.8-346.7; P = 0.01; Figure  4B) 
also when a multivariate analysis was performed (Table S13, 
SDC, http://links.lww.com/TXD/A248). These observations, 
although preliminary, identify miR-148b-5p and miR-744-3p as 
novel players in lung allograft dynamics and open the possibility 
of using these miRNAs as early biomarkers of c-AR.
DISCUSSION
For the first time, our study provides an overview of miRNA 
expression in BAL at different times after bilateral LTx. 
Although preliminary, our data show that the BAL-miRNome 
is significantly modulated 3 months after transplantation and 
that changes in miRNA expression levels in each patient, 
rather than detection at individual schedule, provide clues 
about primary outcome events such as pneumonia and AR. 
In addition, we identified 2 T0-BAL miRNAs, miR-148b-5p 
and miR-744-3p, associated with c-AR risk irrespective of the 
presence of previous infections or other clinical variables.
miRNAs are implicated in the onset, progression, and prog-
nosis of almost all human diseases, and thus represent potential 
novel drug targets. Several lines of evidence have revealed an 
association between miRNA deregulation and inflammation, 
TABLE 2.
Association of clinical variables with clinical AR during the 
first y of follow-up in LTx patients (n = 26), as determined 
by Cox regression model
Covariatea P HR (95% CI)
Recipient (R)
 Recipient diseaseb 0.23 2.68 (0.54-13.34)
 Age ≥ 50 0.77 1.38 (0.25-7.55)
 LAS ≥ 40 0.94 0.94 (0.19-4.67)
Donor (D)
 DBD vs DCD 0.21 3.93 (0.45-33.95)
 Oto > 5 0.13 3.76 (0.68-20.67)
 Smoking history 0.86 0.82 (0.09-7.30)
Mismatch D/R
 Age (D/R ≥ 1.2) 0.72 1.32 (0.27-6.52)
 CMV (Rneg/Dpos) 0.61 1.76 (0.21-14.95)
 Sex mismatch 0.81 1.29 (0.15-11.11)
Surgery
 MP 0.81 1.23 (0.23-6.75)
 Warm ischemia 0.59 1.59 (0.29-8.68)
 ECMO 0.99 1.01 (0.18-5.49)
 MV > 2 d 0.07 4.40 (0.88-21.89)
Posttransplantation events
 PGDc 0.99 1.00 (0.18-5.50)
 Infection_BAL_T0 0.67 0.64 (0.07-5.37)
 Infection_BAL_T1 0.68 1.57 (0.18-13.30)
 Infection_BAL_T2 0.46 1.89 (0.35-10.29)
 Pneumonia 0.21 2.77 (0.56-13.75)
 Best FEV1d 0.81 1.23 (0.23-6.75)
aAll covariates are categorical.
bCystic fibrosis or idiopathic pulmonary fibrosis.
cPatients with PGD grades 0 and 1 or 2 and 3 were grouped together.
dCutoff for FEV1 was set ≥ 80%.
AR, acute rejection; BAL, bronchoalveolar lavage; CI, confidence interval; CMV, cytomegalovirus; 
DBD, donation after brain death; DCD, donation after circulatory death; ECMO, extracorporeal 
membrane oxygenation; FEV1, forced expiratory volume in the first second; HR, hazard ratio; 
LAS, lung allocation score; LTx, lung transplantation; MP, machine perfusion; MV, mechanical 
ventilation; PGD, primary graft dysfunction.
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and preliminary studies have analyzed miRNA content in LTx 
patients.9 Nevertheless, a deeper understanding of miRNA 
dynamics in LTx patients is required to identify the mechanism 
of disease and potential noninvasive biomarkers of graft rejec-
tion. Indeed, although LTx is the only therapy for patients with 
end-stage pulmonary disorders, the rate of chronic rejection is 
still high, and the 5-year survival rate is only 54% (according 
to International Socienty of Heart and Lung Transplantation 
[ISHLT] registry). The ISHLT registry has also reported that 
1-year survival between 2000 and 2009 was significantly 
higher than in 2 preceding eras (1988–1994 and 1995–1999). 
However, the improvement in 5-year survival over this period 
FIGURE 3. miR-148b-5p and miR-744-3p are novel potential predictive biomarkers of acute rejection in lung transplantation (LTx) patients. 
A and B, ROC curves were generated to test the accuracy of the indicated microRNAs (miRNAs) in classifying patients (n = 26) according to 
presence of clinical acute rejection (c-AR) within the first y after LTx. The cutoff for miRNA expression was calculated using Youden’s J statistic. C 
and D, The ROC-generated cutoffs were used to sort LTx patients into LOW or HIGH expression groups for both miR-148b-5p and miR-744-3p 
and their ability to correctly classify LTx patients according to c-AR was analyzed using the enlarged cohort (n = 27). P values are from Fisher 
exact test. E–H, Freedom from c-AR (probability) was estimated using Kaplan-Meier curves in LTx patients within 1 y from transplantation (E and 
F) or during follow-up (G and H). Patients were sorted according to the receiver operating characteristic (ROC)-generated cutoff into high- and 
low-miRNA groups. The number of patients at risk is reported below the curves for all the groups. Indicated P values were computed by the 
log-rank test. AUC, area under the curve; CI, confidence interval; HR, hazard ratio.
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was smaller, suggesting that management strategies have been 
more effective at addressing early complications than later 
ones, possibly via refinements in surgical techniques and post-
operative care. By contrast, survival beyond the first year is 
primarily determined by chronic rejection and infection, and 
the incidences of these complications have not changed sub-
stantially since 1988. Therefore, the clinical management of 
LTx patients could benefit from the adoption of molecular bio-
markers of graft rejection and infections. From this standpoint, 
we preliminarily investigated these issues by identifying several 
potential miRNA markers of early LTx failure, and also pre-
dicted the signaling pathways that these miRNAs target.
Pneumonia-associated miR-23b was previously described 
as a key factor in autoimmune diseases10 and sepsis.11 The tar-
gets of miR-23b include inflammatory cytokines such as tumor 
necrosis factor-α, interleukin-1β, interleukin-17, and vascu-
lar adhesion molecules intercellular adhesion molecule-1, 
E-selectin, and vascular cell adhesion molecule-1. Targeting 
of these molecules by miR-23b protects against autoimmun-
ity but is detrimental in systemic inflammatory states such as 
sepsis, where it contributes to disease progression.11
Among the top pathways predicted to be targeted by 
AR-associated miRNAs, we identified dedifferentiation, 
phenotypic switch, and metabolic changes. These pathways 
might be related to tissue healing and remodeling, processes 
known to be important for organ engrafting and tissue regen-
eration. Remarkably, when tissue regeneration fails fibrosis 
might prevail stimulating aberrant lung remodeling and organ 
dysfunction.12
In keeping with this, we found that miR-29c-5p is signifi-
cantly higher in T1-BAL of patients who experienced PGD 
and it is increased in patients who developed AR. miR-29c 
has been described as an effector of the transforming growth 
factor-β pathway and it is implicated in liver and kidney 
allografts fibrosis, a major hallmark of progressive organ 
dysfunction.13,14
Finally, we identified 2 possible markers predictive of c-AR, 
the BAL-miRNAs miR-148b-4p and miR-744-3p. The levels 
of these 2 molecules 7 days after surgery (T0) could strat-
ify patients by AR risk. Grouping of LTx patients based on 
the levels of both miRNAs revealed that the 2 markers can 
be used simultaneously to improve identification of patients 
likely to have poorer graft outcomes.
Both of these miRNAs have been previously associated 
with inflammatory states. Specifically, miR-744 is upregulated 
in keratinocytes of psoriatic patients15 and the glomeruli of 
diabetic mice,16 and has been shown to boost type I inter-
feron signaling in renal mesangial cells.17 Furthermore, miR-
744 regulates transforming growth factor-β–mediated signal 
transduction.18 On the other hand, deregulation of miR-148b 
has been documented in lung diseases such as CF, where it 
contributes to inflammation and alveolar injury.19 Indeed, 
downregulation of miR-148b promotes endothelial-to-mes-
enchymal transition in endothelial cells, resulting in fibrosis 
and impaired wound closure.20 Consistent with these previous 
reports, we found that high levels of miR-744-3p and low lev-
els of miR-148b-5p were significantly associated with shorter 
time to AR in LTx patients.
One limitation of our study is the small number of enrolled 
patients and the lack of recipients with chronic obstructive 
pulmonary disease as a pretransplantation lung dysfunc-
tion. Further, opposite to previous literature,21 we could not 
determine a correlation between PGD and the development 
of acute graft rejection, although prolonged MV and a poor 
donor Oto score were associated to PGD severity. This could 
be because we excluded from the study subjects that had a 
prolonged ICU stay or that die within the first week after LTx.
Nevertheless, we could confirm our initial data obtained 
with 16 patients including in the cohort 11 additional LTx. 
Altogether, our data provide a preliminary overview of molec-
ular alterations in BAL of LTx patients over a 3-month period 
and suggest novel noninvasive potential markers for patient 
stratification and prognostication. Indeed, the miRNAs-based 
classification could support the definition of a patient-tailored 
immunosuppressive regimen in the first year after LTx.
FIGURE 4. Combination of miR-148b-5p and miR-744-3p classes identifies LTx patients with higher risk of c-AR. A, Combination of the 2 
microRNAs (miRNAs) categories stratifies lung transplantation (LTx) patients (n = 26) in 3 groups with different acute rejection (AR) incidence 
(indicated in the bars). P = 0.01 by chi-square test. B, Forest plot shows the odds ratio of the indicated variables. Bars, 95% confidence 
interval. P values are from logistic regression analysis. CF, cystic fibrosis; CMV, cytomegalovirus; DCD, donation after circulatory death; ECMO, 
extracorporeal membrane oxygenation; LAS, lung allocation score; MP, machine perfusion; MV, mechanical ventilation; PGD, primary graft 
dysfunction.
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As demonstrated for other clinical settings, such as kidney 
inflammatory diseases,17 deregulated expression of miRNAs 
could significantly impact inflammatory signal cascades in the 
pulmonary environment. Although our results need to be vali-
dated in a larger series, they open new opportunities for per-
sonalization of lung allograft management and understanding 
the biological basis of ALAD.
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